Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo
Colleen Annesley(Unknown), Michael C. Jensen(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Qian Wu(Cancer Research Center), Julie Rivers(Seattle Children's Hospital), Adam Brand, Adam J. Lamble(Seattle Children's Hospital), Christopher Brown, Karen Spratt, Corinne Summers(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Catherine Lindgren(Unknown), Adam Johnson(Sana Biotechnology (United States)), Julie R. Park(Seattle Children's Hospital)
Cited by 20
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754